Pratik Mukherjee

Pratik Mukherjee

Auto-generated profile, based on publicly available information

Pratik Mukherjee

Department of Radiology & Biomedical Imaging, UCSF

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
LPLynn K. Paul
Lynn K. Paul
WBWarren S. Brown
Warren S. Brown
RARalph Adolphs
Ralph Adolphs
JTJ. Michael Tyszka
J. Michael Tyszka
LRLinda J. Richards
Linda J. Richards
ESElliott H. Sherr
Elliott H. Sherr

13 February 2008 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
SNS.N. Niogi
S.N. Niogi
PMP. Mukherjee
P. Mukherjee
JGJ. Ghajar
J. Ghajar
CJC. Johnson
C. Johnson
RKR.A. Kolster
R.A. Kolster
BMB.D. McCandliss
B.D. McCandliss
BACKGROUND AND PURPOSE: Diffusion tensor imaging (DTI) may be a useful index of microstructural changes implicated in diffuse axonal injury (DAI) linked to persistent postconcussive symptoms, especially in mild traumatic brain injury (TBI), for which conventional MR imaging techniques may lack sensitivity. We hypothesized that for mild TBI, DTI measures of DAI would correlate with impairments in reaction time, whereas the number of focal lesions on conventional 3T MR imaging would not.

13 March 2008 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
PMP. Mukherjee
P. Mukherjee
JBJ.I. Berman
J.I. Berman
SCS.W. Chung
S.W. Chung
CHC.P. Hess
C.P. Hess
RHR.G. Henry
R.G. Henry
SUMMARY: In this article, the underlying theory of clinical diffusion MR imaging, including diffusion tensor imaging (DTI) and fiber tractography, is reviewed. First, a brief explanation of the basic physics of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping is provided. This is followed by an overview of the additional information that can be derived from the diffusion tensor, including diffusion anisotropy, color-encoded fiber orientation maps, and 3D fiber tractography. This article provides the requisite background for the second article in this 2-part review to appear next month, which covers the major technical factors that affect image quality in diffusion MR imaging, including the acquisition sequence, magnet field strength, gradient amplitude and slew rate, and multichannel radio-frequency coils and parallel imaging. The emphasis is on optimizing these factors for state-of-the-art DWI and DTI based on the best available evidence in the literature.

1 January 2014 in Journal of Neurotrauma
Verified
Journal Article
Closed access
MJMcMahonPaul J.
McMahonPaul J.
HAHricik Allison
Hricik Allison
YKYueJohn K.
YueJohn K.
PMPuccioAva M.
PuccioAva M.
ITInoue Tomoo
Inoue Tomoo
VJVassarMary J.
VassarMary J.
Mild Traumatic Brain Injury (mTBI), or concussion, is a major public health concern. There is controversy in the literature regarding the true incidence of postconcussion syndrome (PCS), with the constellation of physical, cognitive, emotional, and sleep symptoms after mTBI. In the current study, we report on the incidence and evolution of PCS symptoms and patient outcomes after mTBI at 3, 6, and 12 months in a large, prospective cohort of mTBI patients. Participants were identified as part of the prospective, multi-center Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. The study population was mTBI patients (Glasgow Coma Scale score of 13–15) presenting to the emergency department, including patients with a negative head computed tomography discharged to home without admission to hospital; 375 mTBI subjects were included in the analysis. At both 6 and 12 months after mTBI, 82% (n=250 of 305 and n=163 of 199, respectively) of patients reported at least one PCS symptom. Further, 44.5 and 40.3% of patients had significantly reduced Satisfaction With Life scores at 6 and 12 months, respectively. At 3 months after injury, 33% of the mTBI subjects were functionally impaired (Glasgow Outcome Scale-Extended score ≤6); 22.4% of the mTBI subjects available for follow-up were still below full functional status at 1 year after injury. The term “mild” continues to be a misnomer for this patient population and underscores the critical need for evolving classification strategies for TBI for targeted therapy.

1 November 2005 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SMSteven P. Miller
Steven P. Miller
DFDonna M. Ferriero
Donna M. Ferriero
CLCarol Leonard
Carol Leonard
RPRobert Piecuch
Robert Piecuch
DGDavid V. Glidden
David V. Glidden
ABA. James Barkovich
A. James Barkovich

1 January 2014 in Journal of Neurotrauma
Verified
Journal Article
Closed access
DRDiaz- Arrastia Ramon
Diaz- Arrastia Ramon
KWKevin Wang
Kevin Wang
PLPapa Linda
Papa Linda
SDSoraniMarco D.
SoraniMarco D.
YKYueJohn K.
YueJohn K.
VJVassarMary J.
VassarMary J.
Biomarkers are important for accurate diagnosis of complex disorders such as traumatic brain injury (TBI). For a complex and multifaceted condition such as TBI, it is likely that a single biomarker will not reflect the full spectrum of the response of brain tissue to injury. Ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) are among of the most widely studied biomarkers for TBI. Because UCH-L1 and GFAP measure distinct molecular events, we hypothesized that analysis of both biomarkers would be superior to analysis of each alone for the diagnosis and prognosis of TBI. Serum levels of UCH-L1 and GFAP were measured in a cohort of 206 patients with TBI enrolled in a multicenter observational study (Transforming Research and Clinical Knowledge in Traumatic Brain Injury [TRACK-TBI]). Levels of the two biomarkers were weakly correlated to each other (r=0.364). Each biomarker in isolation had good sensitivity and sensitivity for discriminating between TBI patients and healthy controls (area under the curve [AUC] 0.87 and 0.91 for UCH-L1 and GFAP, respectively). When biomarkers were combined, superior sensitivity and specificity for diagnosing TBI was obtained (AUC 0.94). Both biomarkers discriminated between TBI patients with intracranial lesions on CT scan and those without such lesions, but GFAP measures were significantly more sensitive and specific (AUC 0.88 vs. 0.71 for UCH-L1). For association with outcome 3 months after injury, neither biomarker had adequate sensitivity and specificity (AUC 0.65–0.74, for GFAP, and 0.59–0.80 for UCH-L1, depending upon Glasgow Outcome Scale Extended [GOS-E] threshold used). Our results support a role for multiple biomarker measurements in TBI research. (ClinicalTrials.gov Identifier NCT01565551)